Leigh Zawel files SEC Form 4 disclosures for Cullinan Oncology, Inc.. They have made 5 open-market trades across 1 company since 2021, most recently 2022-02-11.
CIK 0001837456
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 69,785 | $901K |
Shares reported on the most recent Form 4, priced at the 2022-02-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL | 2021-10-15 | 2021-10-18 | $25.00 | $489K | +6.2% | -7.2% | -39.6% |
| CGEM | SELL · 10b5-1 | 2021-10-07 | 2021-10-12 | $25.00 | $27K | -4.9% | -5.2% | -37.2% |
| CGEM | SELL | 2021-09-20 | 2021-09-21 | $25.16 | $376K | +4.4% | -1.2% | -32.9% |
| CGEM | SELL | 2021-09-07 | 2021-09-08 | $28.95 | $1.6M | -15.7% | -17.7% | -39.7% |
| CGEM | SELL | 2021-08-23 | 2021-08-26 | $29.00 | $815K | +6.2% | -12.2% | -29.6% |
| CGEM | SELL | 2021-08-09 | 2021-08-26 | $26.77 | $1.4M | +6.2% | -12.2% | -29.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.